Sicong Geng's Colleagues at Elixiron Immunotherapeutics
Sicong Geng's Contact Details
Shanghai,Shanghai,China
Elixiron Immunotherapeutics
Sicong Geng's Company Details
Elixiron employs advances in reverse translational medicine approaches to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary human antibody phage display library and a single human B cell antibody cloning platform to develop innovative therapies for malignant, immunological and degenerative diseases. Our two lead pipeline candidates are currently in first-in-human phase 1 clinical trials. EI-1071, a small molecule inhibitor of CSF1R kinase activity, is being explored as a potential therapy for Alzheimer's disease and to improve cancer immunotherapy by reducing immune suppression in tumors, and EI-001 is a monoclonal antibody being investigated for treatment of Vitiligo and other immunological disorders.